-
Je něco špatně v tomto záznamu ?
Metabolomic, Lipidomic and Proteomic Characterisation of Lipopolysaccharide-induced Inflammation Mouse Model
E. Puris, Š. Kouřil, L. Najdekr, S. Auriola, S. Loppi, P. Korhonen, M. Gómez-Budia, G. Fricker, KM. Kanninen, T. Malm, D. Friedecký, M. Gynther
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- lipidomika * MeSH
- lipopolysacharidy * MeSH
- modely nemocí na zvířatech MeSH
- myši MeSH
- proteomika MeSH
- zánět metabolismus MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Neuroinflammation is an important feature in the pathogenesis and progression of central nervous system (CNS) diseases including Alzheimer's disease (AD). One of the widely used animal models of peripherally induced neuroinflammation and neurodegeneration is a lipopolysaccharide (LPS)-induced inflammation mouse model. An acute LPS administration has been widely used for investigation of inflammation-associated disease and testing inflammation-targeting drug candidates. In the present metabolomic, lipidomic and proteomic study, we investigated short-term effects of systemic inflammation induced by LPS administration on the mouse plasma and brain cortical and hippocampal metabolome, lipidome as well as expression of the brain cortical proteins which were shown to be involved in inflammation-associated CNS diseases. From a global perspective, the hippocampus was more vulnerable to the effects of LPS-induced systemic inflammation than the cortex. In addition, the study revealed several brain region-specific changes in metabolic pathways and lipids, such as statistically significant increase in several cortical and hippocampal phosphatidylcholines/phosphatidylethanolamines, and significantly decreased levels of brain cortical betaine after LPS treatment in mice. Moreover, LPS treatment in mice caused significantly increased protein expression of GluN1 receptor in the brain cortex. The revealed perturbations in the LPS-induced inflammation mouse model may give insight into the mechanisms underlying inflammation-associated CNS diseases. In addition, the finding of the study provide important information about the appropriate use of the model during target validation and drug candidate testing.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025096
- 003
- CZ-PrNML
- 005
- 20240125121212.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuroscience.2022.05.030 $2 doi
- 035 __
- $a (PubMed)35636730
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Puris, Elena $u School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland; Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany. Electronic address: elena.puris@uni-heidelberg.de
- 245 10
- $a Metabolomic, Lipidomic and Proteomic Characterisation of Lipopolysaccharide-induced Inflammation Mouse Model / $c E. Puris, Š. Kouřil, L. Najdekr, S. Auriola, S. Loppi, P. Korhonen, M. Gómez-Budia, G. Fricker, KM. Kanninen, T. Malm, D. Friedecký, M. Gynther
- 520 9_
- $a Neuroinflammation is an important feature in the pathogenesis and progression of central nervous system (CNS) diseases including Alzheimer's disease (AD). One of the widely used animal models of peripherally induced neuroinflammation and neurodegeneration is a lipopolysaccharide (LPS)-induced inflammation mouse model. An acute LPS administration has been widely used for investigation of inflammation-associated disease and testing inflammation-targeting drug candidates. In the present metabolomic, lipidomic and proteomic study, we investigated short-term effects of systemic inflammation induced by LPS administration on the mouse plasma and brain cortical and hippocampal metabolome, lipidome as well as expression of the brain cortical proteins which were shown to be involved in inflammation-associated CNS diseases. From a global perspective, the hippocampus was more vulnerable to the effects of LPS-induced systemic inflammation than the cortex. In addition, the study revealed several brain region-specific changes in metabolic pathways and lipids, such as statistically significant increase in several cortical and hippocampal phosphatidylcholines/phosphatidylethanolamines, and significantly decreased levels of brain cortical betaine after LPS treatment in mice. Moreover, LPS treatment in mice caused significantly increased protein expression of GluN1 receptor in the brain cortex. The revealed perturbations in the LPS-induced inflammation mouse model may give insight into the mechanisms underlying inflammation-associated CNS diseases. In addition, the finding of the study provide important information about the appropriate use of the model during target validation and drug candidate testing.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a zánět $x metabolismus $7 D007249
- 650 12
- $a lipidomika $7 D000081362
- 650 12
- $a lipopolysacharidy $7 D008070
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a proteomika $7 D040901
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kouřil, Štěpán $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, Hněvotínská 5, 77900 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I.P. Pavlova 6, 77900 Olomouc, Czech Republic $7 xx0313061
- 700 1_
- $a Najdekr, Lukáš $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, Hněvotínská 5, 77900 Olomouc, Czech Republic
- 700 1_
- $a Auriola, Seppo $u School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
- 700 1_
- $a Loppi, Sanna $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland; Department of Immunobiology, University of Arizona, 1656 E Mabel Street, Tucson, AZ 85724-5221, United States
- 700 1_
- $a Korhonen, Paula $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
- 700 1_
- $a Gómez-Budia, Mireia $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
- 700 1_
- $a Fricker, Gert $u Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany
- 700 1_
- $a Kanninen, Katja M $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
- 700 1_
- $a Malm, Tarja $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
- 700 1_
- $a Friedecký, David $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, Hněvotínská 5, 77900 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I.P. Pavlova 6, 77900 Olomouc, Czech Republic
- 700 1_
- $a Gynther, Mikko $u School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland; Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany
- 773 0_
- $w MED00003505 $t Neuroscience $x 1873-7544 $g Roč. 496, č. - (2022), s. 165-178
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35636730 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20240125121207 $b ABA008
- 999 __
- $a ok $b bmc $g 1854681 $s 1176386
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 496 $c - $d 165-178 $e 20220528 $i 1873-7544 $m Neuroscience $n Neuroscience $x MED00003505
- LZP __
- $a Pubmed-20221017
